TW-37, a novel molecular inhibitor of BCL2 with anti-angiogenic properties

Authors

Benjamin David Zeitlin, University of the PacificFollow
Esther Joo, University of Michigan School of DentistryFollow
Guo-Liang Wang, The Ohio State UniversityFollow
Shaomeng Wang, University of Michigan - Ann ArborFollow
Jacques E. Nör, University of Michigan School of DentistryFollow

ORCiD

Dr. Benjamin D. Zeitlin: 0000-0003-0110-0188

Department

Biomedical Sciences

Document Type

Conference Presentation

Conference Title

Anti-Angiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back

Organization

American Association for Cancer Research

Location

Waltham, Massachussetts

Conference Dates

November 9-13, 2005

Date of Presentation

11-9-2005

Comments

AACR Previous Meetings Listing for 2005: http://www.aacr.org/Meetings/Pages/previous-aacr-meetings-2005.aspx#.Wd3nQNN97R0

Recommended Citation

Zeitlin, B. D., Joo, E., Wang, G., Wang, S., & Nör, J. E. (2005). TW-37, a novel molecular inhibitor of BCL2 with anti-angiogenic properties. Paper presented at Anti-Angiogenesis and Drug Delivery to Tumors: Bench to Bedside and Back in Waltham, Massachussetts.
https://scholarlycommons.pacific.edu/dugoni-facpres/91